20260515 Press Release Q4 & FY26
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong Q4 FY26 results with standalone revenue up 22% and PAT up 174% year-on-year. For the full year FY26, standalone revenue grew 2% and PAT grew 64%, while consolidated revenue rose 7% with PAT up 99%. The Poultry Healthcare Division drove growth with 41% Q4 revenue increase, while the Animal Healthcare Division faced headwinds from delayed government immunisation programmes. EBITDA margin expanded significantly by 11 percentage points on standalone basis to 30%. The board recommended a dividend of INR 11 per share (110%) and re-appointed Ms. Priya Gandhi as Executive Director for 3 years from October 2026. The company received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine and capitalised its BSL 3 facility.
Strong profitability growth and margin expansion signal operational improvement. The clean audit opinion and dividend declaration are positive for shareholders. Growth is primarily driven by the poultry segment while animal healthcare remains challenged.